Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group.

@article{Fogelman2000RisedronateRB,
  title={Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group.},
  author={Ignac Fogelman and Claude A Ribot and Rosita Smith and Dominique J Ethgen and E W Sod and Jean-Yves Reginster},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2000},
  volume={85 5},
  pages={1895-900}
}
Our objective was to investigate the efficacy and tolerability of risedronate in postmenopausal women with low bone mass. Women with a mean lumbar spine T-score of -2 or less (n = 543) received 24 months of placebo or risedronate (2.5 or 5 mg/day). All received calcium (1 g/day). The principal outcome measures were bone mineral density (BMD) at the lumbar spine, femoral neck, and femoral trochanter. At 24 months, lumbar spine BMD increased from baseline by 4% with 5 mg risedronate and 1.4% in… CONTINUE READING